Analyst firms Citi and BofA adjust their price targets for Lam Research as they anticipate elevated spending on chip manufacturing. According to the Yahoo Finance updates, Citi increases its target by $135, citing a multi-year investment cycle that supports demand for semiconductor equipment. Separately, Yahoo Finance reports BofA raises its target by $150 as chip equipment spending is projected to move toward roughly $250 billion. Both notes frame Lam Research’s outlook in the context of an industry-wide spending expansion, rather than any single company-specific operational change. The articles present the revisions as part of broader changes to forward expectations for semiconductor capital expenditure and equipment demand. The sources do not provide additional details in the excerpts about financial results, guidance, or specific customer orders; the central shared point is that both Citi and BofA lift their Lam Research targets alongside expectations for continued, high levels of chip production investment.
Citi and BofA raise targets for Lam Research amid forecast chip-manufacturing investment boom
Analyst firms Citi and BofA adjust their price targets for Lam Research as they anticipate elevated spending on chip manufacturing. According to the Yahoo Finance updates, Citi increases its target by...
1 sources
3 hours ago
1 views
Key Points
- Citi raises its price target for Lam Research by $135.
- BofA raises its price target for Lam Research by $150.
- Both updates link the target increases to expectations for higher semiconductor equipment spending.
- Chip equipment spending is forecast to approach about $250 billion.
- The reports are presented as analyst outlook changes rather than citing new company-specific developments in the provided excerpts.
How Outlets Covered This Story
YAH
Yahoo Finance
Lam Research (LRCX): BofA Raises Its Target by $150 as Chip Equipment Spending Heads Toward $250 Billion
2 hours ago
YAH
Yahoo Finance
Lam Research (LRCX): Citi Raises Target by $135 on a Multi-Year Chip Manufacturing Investment Boom
4 hours ago
Related Stories
Ipsen to acquire Kartos Therapeutics in up-to-$1.75 billion oncology deal
Ipsen announces it will acquire U.S. biotech Kartos Therapeutics to expand its oncology pipeline. Multiple outlets repor...
3 sources
4 hours ago
Strategy (MSTR) adopts capital framework authorizing buybacks, higher STRC dividend, and possible BTC monetization
Strategy Inc. (Nasdaq: MSTR) announces a new capital management framework it says is designed to preserve Bitcoin exposu...
3 sources
1 hour ago
Saks Global exits bankruptcy and rebrands as Exemplar Luxury Group
Saks Global, the parent company of Saks Fifth Avenue, Neiman Marcus, and Bergdorf Goodman, exits bankruptcy and rebrands...
2 sources
2 hours ago